Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
Released
Released
Announcement PDF
Immuron CEO, Steven Lydeamore to present at Coffee
Microcaps
Melbourne, Australia, March 14, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally
integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be
presenting at the Coffee Microcaps conference in Sydney on March 14th.
A copy of the presentation being made at the Coffee Microcaps conference in Sydney is included below.
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
- - - END - - -
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and
commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting
travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken
with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea.
In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated
to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
Travelers’ diarrhea (TD)
TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea,
vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of
returning from any resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem
among travelers to destinations in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially
representing a long-term traveller population, are particularly affected given their population dynamics and the context in which
they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and
preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most
commonly reported etiologies (Riddle et al., 2006).
Immuron Platform Technology
Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine
colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive
enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI
tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology
enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or
bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
IMM-124E
IMM-124E was developed using Immuron’s platform technology. IMM-124E is produced from the colostrum of birthing cattle
that have been immunised during pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total
of 13 ETEC strains are used in the vaccine to produce high levels of antibodies against selected surface antigens from the most
common strains of ETEC.
The resultant hyperimmune colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies
specific for ETEC antigens LPS, CFA-I and Flagellin (Sears et al., 2017).
The antibodies produced in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies
of unvaccinated cattle) against a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved
oligosaccharide core ‘R’ region of LPS from the 13 serotypes used in the ETEC vaccine.
IMM-124E is manufactured into a tablet form referred to as Travelan®.
References
Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin
Infect Dis. 25(5): 546-54; 2012.
Leung AK, Robson WL, Davies HD. Travelers’ diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006
Otto W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine
colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862– 868;
2011.
Riddle MS, Sanders JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers’ (US military and
similar populations): A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.
Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of
Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14;
2017.
Steffen R. Epidemiology of travelers' diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Subscribe for Immuron News: Here
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject
to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results
to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing
clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on
which any such statement is based, except as required by law.
INVESTOR
PRESENTATION
COFFEE MICROCAPS
14 MARCH 2024
S t e v e n Ly d e a m o r e - C E O
NASDAQ: IMRN
ASX: IMC
1
SAFE HARBOR STATEMENT
C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re
b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s
“a nt i c i p a t e s ,” “ex p e c t s ,” “ i nte n d s ,” “ p l a n s ,” “ b e l i e ve s ,” “s e e ks ,” “e st i m a te s ,” “g u i d a n c e ”
a n d s i m i l a r ex p re s s i o n s a re i nte n d e d to i d e nt i f y fo r wa rd - l o o k i n g state m e n t s .
A l t h o u g h I m m u ro n b e l i e v e s t h e fo r wa rd - l o o k i n g state m e n t s a re b a s e d o n
re a s o n a b l e a s s u m p t i o n s , t h ey a re s u b j e c t to c e r ta i n r i s ks a n d u n c e r ta i n t i e s ,
s o m e o f w h i c h a re b eyo n d I m m u ro n ’s c o nt ro l , i n c l u d i n g t h o s e r i s ks o r
u n c e r ta i n t i e s i n h e re n t i n t h e p ro c e s s o f b o t h d e ve l o p i n g a n d c o m m e rc i a l i z i n g
te c h n o l o g y. A s a re s u l t , a c t u a l re s u l t s c o u l d m ate r i a l l y d i ffe r f ro m t h o s e
ex p re s s e d o r fo re ca ste d i n t h e fo r wa rd - l o o k i n g state m e n t s .
T h e fo r wa rd - l o o k i n g state m e n t s m a d e i n t h i s p re s e n ta t i o n re l ate o n l y to
e ve nt s a s o f t h e d ate o n w h i c h t h e state m e n t s a re m a d e . I m m u ro n w i l l n o t
u n d e r ta ke a ny o b l i gat i o n to re l e a s e p u b l i c l y a ny re v i s i o n s o r u p d ate s to
t h e s e fo r wa rd - l o o k i n g state m e n t s to ref l e c t e ve nt s , c i rc u m sta n c e s o r
u n a nt i c i p a te d e ve nt s o c c u r r i n g a f te r t h e d ate o f t h i s p re s e nta t i o n exc e p t a s
re q u i re d b y l aw o r b y a ny a p p ro p r i a te re g u l ato r y a u t h o r i t y.
F Y 2 0 2 4 re s u l t s i n t h i s p re s e nta t i o n a re s u b j e c t to a u d i t re v i e w.
2
REVENUE GENERATING WITH STRONG PIPELINE
Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and
commercialising, oral immunotherapeutics for the treatment of gut mediated diseases
Financial Snapshot
Shares on Issue
Total Options
Last Traded
Price
Market Cap.
Cash & Cash
Equivalents
Sales Revenue
Gross Profit
30-Jun-23 (FY)
7-Mar-24 (FYTD)
227,798,346
12,879,720
227,798,346
15,568,559
IMC: A$0.075
IMC: A$0.125
IMC: A$17.1m
IMC: A$28.5m
A$17.2m
A$15.2m (31-Dec-23)
FY23 A$1.8m
FY23 A$1.3m
A$3.2m +168% on pcp
A$2.2m +147% on pcp
3
REVENUE GENERATING WITH STRONG PIPELINE
Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and
commercialising, oral immunotherapeutics for the treatment of gut mediated diseases
Pipeline Snapshot
30-Jun-23
7-Mar-24
Travelan (IMM-124E) Phase 2
Traveller’s Diarrhoea
Travelan® (IMM-124E) –
Phase 4
Traveller’s Diarrhoea
Initiated IMM-124E ETEC2 CHIM3 clinical
trial
Topline results for IMM-124E ETEC2 clinical
trial
USU4 P2TD IMM-124E field clinical trial
recruited 35% of 868 participants
Recruited 50% of 868 participants
CampETEC – Phase 2
Campylobacteriosis
FDA IND1 approved (Clinical Hold
released)
Completion of In-patient phase
Campylobacter CHIM3 clinical trial
IMM-529 – Phase 2
Clostridioides Difficile
Completed 600 mg solid dose active
formulation development
Completion of IMM-529 drug substance
manufacture by CSIRO
1. Investigational New Drug; 2. Enterotoxigenic E.coli; 3. controlled human infection model; 4. Uniformed Health Services University of the Health Sciences
4
TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES
Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase,
growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to
milk. This enables full development of the newborn calf in addition to immunity against several pathogens.*
Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with
a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and
can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces.
STEP 1
Development of Highly
Specific Vaccines
STEP 2
Isolation of Hyperimmune
antibody-rich
bovine colostrum
* Gomes et. al., NFS Journal, Volume 25, November 2021, pages 111, https://doi.org/10.1016/j.nfs.2021.10.001
STEP 3
Oral Antimicrobial
therapeutics
without drawbacks
of antibiotics
FINAL PRODUCT
Toxin Neutralization +
Clearance of targeted gut
pathogens
✓ Reduce occurrence and
reduce/relieve diarrhoea
✓ Reduce/relieve abdominal
cramping
✓ Reduce/relieve gastrointestinal
pain
✓ Assists repair of
gastrointestinal/gut wall lining
✓ Enhance/promote immune
defence
✓ Enhance/promote health liver
function
Australian Permitted indications;
these statements have not been
evaluated by the Food and Drug
Administration (FDA)
5
STRONG PIPELINE WITH NEAR TERM MILESTONES
Immuron’s Clinical Programs
Compound or
brand name
Indication
IMM-124E
Travelan®
Traveler’s
Diarrhea ETEC
challenge
IMM-529
Clostridioides
difficile
Infection &
Recurrence
Phase
I
Phase
II
Phase
III
Market
Our Partners’ Clinical Programs
Compound or
brand name
Partner
Phase
I
Phase
II
Phase
III
Market
Travelan®
Uniformed Services University
CampETEC
Naval Medical
Research
Command
Further information on the clinical programs can be found on slide 8
6
VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS
Lumanity*
CorporateOpportunity
Assessment for IMM-124E
›
›
›
›
Immuron’s development of IMM-124E (hyperimmune
bovine colostrum) as a prescription medication has
the potential to address this unmet need
Primary care physicians (PCP)s impressed with clinical
efficacy endpoint targets demonstrating > 80%
protection against the development of diarrhea.
If base case efficacy targets are reached, IMM-124E
would mostly be used by travelers going to the
highest risk areas (e.g., rural Central
America/Asia/Africa).
Based on the estimated market size and pricing, the
base case yearly revenue in USA for IMM-124E is
projected at US$102M.
Reaching higher efficacy goals could broaden use.
Compound or brand name
Indication
IMM-124E - Travelan®
Traveler’s Diarrhea ETEC challenge
IMM-529
Clostridioides difficile Infection & Recurrence
›
›
Opportunity
Lumanity
Corporate
Assessment for IMM-529
›
›
›
Infectious disease experts reacted favorably to the IMM-529
MOA, and its unique ability to target three elements of the
rCDI infection – the spores, vegetative cells, and Toxin B
Non-microbiome approaches (such as IMM-529) are still
appealing to experts, who noted that clinical trial efficacy
(reduction in relapse rate) and cost/access will be the key
drivers of clinical use in recurrent patients, not mechanism
of action
Based on the estimated market size, anticipated payer
restrictions, pricing, and competition, base case yearly
revenue in USA for IMM-529 is conservatively projected at
US$93M for the target patient population (limited to 2nd
recurrence and later based on trial design and payer
coverage)
Positioning IMM-529 earlier than second recurrence and/or
efficacy targets could lead to higher uptake.
Phase I
Phase II
Phase III
Lumanity, a leading lifescience consulting company: https://lumanity.com/company/our-story/
Clostridioides difficile infections (CDI) to grow to almost $1.7 billion by 2026, according to GlobalData
Market
7
NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE
2H 2022
1H 2023
2H 2023
FDA IND1 approved for
•
single daily dose IMM•
124E ETEC2 CHIM3 clinical
trial
IRB Approval4
•
Initiated IMM-124E ETEC2 •
CHIM3 clinical trial
100% of patients enrolled •
Completion of In-patient
phase ETEC2 CHIM3
clinical trial
Topline results for IMM- •
124E ETEC2 clinical trial •
Clinical Study Report
End of Phase 2 FDA
meeting
•
Submitted Response
•
Letter to FDA Clinical Hold •
Immuron sponsored
Toxicology study completed
Toxicology Study Report
FDA IND1 approved
(Clinical Hold released)
•
Institutional Review
•
5
Board approval of NMRC
CampETEC
Campylobacter CHIM3
clinical trial protocol
Initiated IMM-124E
Campylobacter CHIM3
clinical trial
IMM-529 cGMP
•
manufacture
~50% of 868 participants •
recruited
•
Completion of Inpatient phase
CampETEC
Campylobacter CHIM3
clinical trial
•
Topline results for
CampETEC
Campylobacter CHIM3
clinical trial
IMM-529 (CDI)7 PreIND1 submission
Completion of
enrollment
Completion of inpatient phase
•
FDA meeting
•
Topline results
•
CampETEC
•
•
•
Travelan®
2H 2024
•
Travelan®
IMM-529
1H 2024
600 mg solid dose active
formulation development
USU6 P2TD IMM-124E
field clinical trial
recruitment
commencement
•
•
Completed; 1. Investigational New Drug; 2. Enterotoxigenic E.coli; 3. controlled human infection model; 4. Institutional Review Board; 5. Naval Medical Research Command;
6. Uniformed Health Services University of the Health Sciences; 7. Clostridioides Difficile
8
IMM-124E
BILLION DOLLAR MARKET
- HIGH UNMET NEED
Billion Dollar Market
Traveller’s diarrhoea treatment market
is large and growing at a CAGR of ~7%
Industry tailwinds
Travel picking up significantly following
COVID lockdowns
Frequent Symptoms
30% - 70% of travelers experience traveller’s diarrhoea1
•
•
•
•
•
•
There are no current reliable vaccines for prevention of Travellers’ diarrhoea1
Enterotoxigenic Escherichia coli (ETEC) is the leading cause of Travellers’ diarrhoea1
Travelan® is a hyperimmune bovine colostrum produced by immunization of cows during gestation
with a vaccine consisting of antigens derived from 13 different ETEC strains known to cause
Travelers’ diarrhea
Travelan® is broadly cross-reactive with other ETEC strains not included in the vaccine and other
gram-negative bacteria (Shigella, Vibrio cholera, Campylobacter spp.)2,3
Diarrhea ranked 1st among 57 infectious disease threats by the 2019 Military Infectious Disease
Research Program’s Infectious Disease Threat Prioritization Panel based on its impact to readiness4
76% of Soldiers in OIF and OEF experienced traveler’s diarrhea early in their deployment4
1 Centers for Disease Control and Prevention CDC.gov 2024; 2 Sears et al., Clin. Vaccine Immunol. 2017 https://doi.org/10.1128/cvi.00186-16; 3 Islam et al., PLOS one 2023
https://doi.org/10.1371/journal.pone.0294021;; 4 Olson et al. “Tropical Diseases, Travel Medicine and Vaccines, 2019, 51-15 Page 3; OIF (Operation Iraqi Freedom); OEF (Operation
Enduring Freedom)
9
• Positive Results Support Travelan®
progress to Phase 3
• IMM-124E Phase 2
•
•
•
•
•
•
•
•
•
Healthy volunteers were recruited and randomized to receive a single
daily oral dose of 1200 mg of Travelan® or placebo. Dosing commenced
2 days prior to challenge with ETEC strain H10407 and continued for 7
days.
• 60 subjects completed the inpatient challenge component of this
current clinical study.
Travelan® topline clinical trial results demonstrate protective efficacy with
single daily dose
36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group
compared to the placebo group (primary endpoint) even though the attack rate for this study was 37%, much lower than the expected 70%
The attack rates on previous Phase 2 (Otto et al. 2011) studies were 73% and 86% with protective efficacy of 90.9% and 76.7%
66.7% protective efficacy against ETEC induced severe diarrhea was observed in the Travelan® group compared to the placebo group (secondary
endpoint)
83.3% statistically significant reduction in the number of subjects in the Travelan® group requiring early antibiotic treatment post challenge compared
to the placebo (secondary endpoint)
100% of the subjects requiring IV fluids post challenge were in the placebo (secondary endpoint)
55.6% reduction in the number of subjects experiencing adverse events associated with the ETEC challenge observed in the Travelan® group compared
to the placebo group (secondary endpoint)
Phase 2 clinical study data supports the excellent safety and tolerability profile of Travelan®
10
IMM-124E PHASE 3 STRATEGY
Pre
•
•
•
•
2H 2024
Phase 1 clinical study •
(Baltimore, 1996)
•
Phase 2 clinical study
(Poland, 2000)
FDA1 IND2 approval
(December 2022)
Phase 2 clinical study
(Baltimore, 2024)
Clinical Study Report •
End of Phase 2 FDA
meeting
1H 2025
Phase 3 FDA meeting •
2H 2025
Initiate Phase 3
Post
•
•
•
Trial duration ~ 2
years
End of Phase 3 FDA
meeting
BLA3 submission
•
The pivotal registration studies will involve two randomized, double-blind, parallel-group, placebo-controlled Phase 3
clinical studies (drug substance IMM-124E) to assess the efficacy and safety of Travelan® for prevention of traveler’s
diarrhea (TD)
•
The studies will enroll approximately 1200 healthy adult subjects (600 subjects in two studies) traveling to regions with high
TD risk.
Subjects will be randomized 1:1 to receive Travelan® or placebo.
Dosing will begin 3 days prior to arrival in country and for at least 14 days in country.
The primary endpoint will be the development of TD.
•
•
•
1. U.S. Food and Drug Administration; 2. Investigational New Drug; 3. Biologics License Application
11
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI
IMM-529
Indication / Target
Population
IMM-529 will be indicated for the treatment of recurrent C. difficile
infection
Product
Description /
Mechanism of
Action
• Novel antibody-containing therapeutic which neutralizes C. difficile
but does not impact the microbiome
• Targets not only toxin B but also spores and vegetative cells
responsible for recurrence
• Potential for use in combination with standard of care (e.g.
vancomycin, metronidazole)
• Targets many isolates
Dosage and ROA
• Oral administration, 3 x daily
• Trial to test 28-day treatment course on top of standard of care
(vancomycin, metronidazole)
Efficacy
• Mouse data demonstrated ~80% survival rate (7/9) vs. ~10% survival
rate in a control group (1/9) in a recurrent CDI mouse model
Safety / Tolerability
• To be evaluated in Phase I/IIA study
• Equivalent or better than current standard of care
12
SCIENTIFIC REFERENCES
Travelan® (IMM-124E)
Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90%
of volunteers
Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI:
10.3109/00365521.2011.574726
Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers’ Diarrhea in Active Duty
Military Service Assigned Abroad.
Military Health System Research Symposium 14-17 Aug 2023_Abstract 1
Travelan as a broad Spectrum anti-bacterial
Immuron Limited, 29 April, 2011
Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad
potential for prevention of traveler’s diarrhea
US Department of Defense, Armed Forces Research Institute of Medical Sciences
(AFRIM), 4 September, 2019
Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared
to placebo and demonstrated a significant clinical benefit
US Department of Defense, Armed Forces Research Institute of Medical Sciences
(AFRIM), 5 September, 2018
Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and
Shigella
US Department of Defense, Armed Forces Research Institute of Medical Sciences
(AFRIM), 30 January, 2017
Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a nonHuman primate model (Macaca mulatta)
Islam D, Ruamsap N, Imerbsin R, Khanijou P, Gonwong S, Wegner MD, et al. (2023)
Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against
shigellosis in a non-Human primate model (Macaca mulatta). PLoS ONE 18(12):
e0294021.
Bioactive Immune Components of Travelan®
Clin Vaccine Immunol 24:e00186-16. https://doi.org/10.1128/CVI.00186-16
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM-124E) has a non-detrimental
effect on gut microbial communities in unchallenged mice
Infect Immun. 2023 Nov; 91(11): e00097-23.
Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine
Colitis
Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785–797,
https://doi.org/10.1093/ecco-jcc/jjy213
IMM-529
Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic
alternative
Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5
13
STEVEN LYDEAMORE
CHIEF EXECUTIVE OFFICER
IMMURON LIMITED
CONTACT INFORMATION:
EMAIL: STEVE@IMMURON.COM
PHONE: AUSTRALIA: +61 438 027 172
14
Share your feedback
Discover